Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback

Paradigm Biopharmaceuticals Limited (ASX: PAR) entered voluntary administration on 29 September 2026, with Hayden White and Christopher Pattinson of FTI Consulting appointed joint and several administrators after the Melbourne-based biotechnology company suffered a setback in a critical Phase 3 clinical trial. The administrators have taken control of Paradigm’s business, operations and assets and are assessing its financial position, future viability and potential restructuring options.

Paradigm is developing a potential treatment for knee osteoarthritis based on injectable pentosan polysulfate sodium. Its Phase 3 PARA_OA_012 trial had enrolled 538 participants, but the company recently announced that the trial would not proceed as planned after an interim efficacy result fell below the pre-specified threshold required for continuation.

The clinical setback created an immediate financing problem for the company. Paradigm had received a US$2 million advance from Obsidian Global GP, LLC under a US$27 million convertible note facility intended to support the clinical program and subsequently announced that the advance would be repaid. The administration followed discussions with Obsidian over the financial consequences of the interim trial result and possible restructuring options. Paradigm's board said the company faces a mismatch between liabilities payable in the short term and what it views as the longer-term value of its intellectual property portfolio.

The board intends to work with the administrators, Obsidian and other stakeholders on a proposed deed of company arrangement. The contemplated restructuring would seek to address Paradigm's liabilities, preserve its intellectual property and available clinical data, and determine whether there is a viable path forward for the business. Any proposal remains subject to consideration by the administrators and approval by creditors.

Paradigm also plans to continue analysing the available Phase 3 data and reviewing its clinical program, subject to the administrators' assessment and available resources. The review will examine the interim outcome, including the effect of missing data, and assess potential future development and commercial options. Paradigm expects the clinical review and restructuring process to take at least eight weeks, although the timetable could be extended.

The company's shares, which were suspended from trading on the ASX before the administration, are expected to remain suspended while the process continues. The first meeting of creditors is expected to be held on 9 October.